Top

Published in:

01-06-2019 | Obesity | REVIEW

Review: the Roles and Mechanisms of Glycoprotein 130 Cytokines in the Regulation of Adipocyte Biological Function

Authors: Dufang Ma, Yong Wang, Guofeng Zhou, Yongcheng Wang, Xiao Li

Published in: Inflammation | Issue 3/2019

Abstract

Chronic low-grade inflammation is now widely accepted as one of the most important contributors to metabolic disorders. Glycoprotein 130 (gp130) cytokines are involved in the regulation of metabolic activity. Studies have shown that several gp130 cytokines, such as interleukin-6 (IL-6), leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), and cardiotrophin-1 (CT-1), have divergent effects on adipogenesis, lipolysis, and insulin sensitivity as well as food intake. In this review, we will summarize the present knowledge about gp130 cytokines, including IL-6, LIF, CNTF, CT-1, and OSM, in adipocyte biology and metabolic activities in conditions such as obesity, cachexia, and type 2 diabetes. It is valuable to explore the diverse actions of these gp130 cytokines on the regulation of the biological functions of adipocytes, which will provide potential therapeutic targets for the treatment of obesity and cachexia.

White, U.A., and J.M. Stephens. 2011. The gp130 receptor cytokine family: Regulators of adipocyte development and function. Current Pharmaceutical Design 17 (4): 340–346.CrossRef

Fujio, Y., M. Maeda, T. Mohri, M. Obana, T. Iwakura, A. Hayama, T. Yamashita, H. Nakayama, and J. Azuma. 2011. Glycoprotein 130 cytokine signal as a therapeutic target against cardiovascular diseases. Journal of Pharmacological Sciences 117 (4): 213–222.CrossRef

Ernst, M., and B.J. Jenkins. 2004. Acquiring signalling specificity from the cytokine receptor gp130. Trends in Genetics 20 (1): 23–32. https://doi.org/10.1016/j.tig.2003.11.003.CrossRefPubMed

Kajimura, S. 2017. Adipose tissue in 2016: advances in the understanding of adipose tissue biology. Nature Reviews. Endocrinology 13 (2): 69–70. https://doi.org/10.1038/nrendo.2016.211. CrossRefPubMedPubMedCentral

Murakami, S. 2017. The physiological and pathophysiological roles of taurine in adipose tissue in relation to obesity. Life Sciences 186: 80–86. https://doi.org/10.1016/j.lfs.2017.08.008. CrossRefPubMed

White, U.A., W.C. Stewart, and J.M. Stephens. 2011. Gp130 cytokines exert differential patterns of crosstalk in adipocytes both in vitro and in vivo. Obesity (Silver Spring) 19 (5): 903–910. https://doi.org/10.1038/oby.2010.293.CrossRef

Fruhbeck, G., J. Gomez-Ambrosi, F.J. Muruzabal, and M.A. Burrell. 2001. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. American Journal of Physiology. Endocrinology and Metabolism 280 (6): E827–E847. https://doi.org/10.1152/ajpendo.2001.280.6.E827.CrossRefPubMed

Mohamed-Ali, V., S. Goodrick, A. Rawesh, D.R. Katz, J.M. Miles, J.S. Yudkin, S. Klein, and S.W. Coppack. 1997. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. The Journal of Clinical Endocrinology and Metabolism 82 (12): 4196–4200. https://doi.org/10.1210/jcem.82.12.4450.CrossRefPubMed

Lazar, M.A. 2005. How obesity causes diabetes: not a tall tale. Science 307 (5708): 373–375. https://doi.org/10.1126/science.1104342.CrossRefPubMed

10.

Sabio, G., M. Das, A. Mora, Z. Zhang, J.Y. Jun, H.J. Ko, T. Barrett, J.K. Kim, and R.J. Davis. 2008. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 322 (5907): 1539–1543. https://doi.org/10.1126/science.1160794.CrossRefPubMedPubMedCentral

11.

Klover, P.J., T.A. Zimmers, L.G. Koniaris, and R.A. Mooney. 2003. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52 (11): 2784–2789.CrossRef

12.

Khaodhiar, L., P.R. Ling, G.L. Blackburn, and B.R. Bistrian. 2004. Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity. JPEN Journal of Parenteral and Enteral Nutrition 28 (6): 410–415. https://doi.org/10.1177/0148607104028006410.CrossRefPubMed

13.

Bastard, J.P., C. Jardel, E. Bruckert, P. Blondy, J. Capeau, M. Laville, H. Vidal, and B. Hainque. 2000. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. The Journal of Clinical Endocrinology and Metabolism 85 (9): 3338–3342. https://doi.org/10.1210/jcem.85.9.6839.CrossRefPubMed

14.

Matthews, V.B., T.L. Allen, S. Risis, M.H. Chan, D.C. Henstridge, N. Watson, L.A. Zaffino, et al. 2010. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 53 (11): 2431–2441. https://doi.org/10.1007/s00125-010-1865-y. CrossRefPubMed

15.

Wallenius, V., K. Wallenius, B. Ahren, M. Rudling, H. Carlsten, S.L. Dickson, C. Ohlsson, and J.O. Jansson. 2002. Interleukin-6-deficient mice develop mature-onset obesity. Nature Medicine 8 (1): 75–79. https://doi.org/10.1038/nm0102-75.CrossRefPubMed

16.

Mauer, J., B. Chaurasia, J. Goldau, M.C. Vogt, J. Ruud, K.D. Nguyen, S. Theurich, A.C. Hausen, J. Schmitz, H.S. Brönneke, E. Estevez, T.L. Allen, A. Mesaros, L. Partridge, M.A. Febbraio, A. Chawla, F.T. Wunderlich, and J.C. Brüning. 2014. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nature Immunology 15 (5): 423–430. https://doi.org/10.1038/ni.2865. CrossRefPubMedPubMedCentral

17.

Scheller, J., A. Chalaris, D. Schmidt-Arras, and S. Rose-John. 2011. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica et Biophysica Acta 1813 (5): 878–888. https://doi.org/10.1016/j.bbamcr.2011.01.034.CrossRefPubMed

18.

Kraakman, M.J., T.L. Allen, M. Whitham, P. Iliades, H.L. Kammoun, E. Estevez, G.I. Lancaster, and M.A. Febbraio. 2013. Targeting gp130 to prevent inflammation and promote insulin action. Diabetes, Obesity & Metabolism 15 (Suppl 3): 170–175. https://doi.org/10.1111/dom.12170.CrossRef

19.

Jostock, T., J. Mullberg, S. Ozbek, R. Atreya, G. Blinn, N. Voltz, M. Fischer, M.F. Neurath, and S. Rose-John. 2001. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. European Journal of Biochemistry 268 (1): 160–167.CrossRef

20.

Kraakman, M.J., H.L. Kammoun, T.L. Allen, V. Deswaerte, D.C. Henstridge, E. Estevez, V.B. Matthews, B. Neill, D.A. White, A.J. Murphy, L. Peijs, C. Yang, S. Risis, C.R. Bruce, X.J. du, A. Bobik, R.S. Lee-Young, B.A. Kingwell, A. Vasanthakumar, W. Shi, A. Kallies, G.I. Lancaster, S. Rose-John, and M.A. Febbraio. 2015. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metabolism 21 (3): 403–416. https://doi.org/10.1016/j.cmet.2015.02.006.CrossRefPubMed

21.

Sun, K., J. Tordjman, K. Clement, and P.E. Scherer. 2013. Fibrosis and adipose tissue dysfunction. Cell Metabolism 18 (4): 470–477. https://doi.org/10.1016/j.cmet.2013.06.016.CrossRefPubMedPubMedCentral

22.

Sun, K., J. Park, O.T. Gupta, W.L. Holland, P. Auerbach, N. Zhang, R. Goncalves Marangoni, S.M. Nicoloro, M.P. Czech, J. Varga, T. Ploug, Z. An, and P.E. Scherer. 2014. Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nature Communications 5: 3485. https://doi.org/10.1038/ncomms4485.CrossRefPubMedPubMedCentral

23.

Sun, K., N. Halberg, M. Khan, U.J. Magalang, and P.E. Scherer. 2013. Selective inhibition of hypoxia-inducible factor 1alpha ameliorates adipose tissue dysfunction. Molecular and Cellular Biology 33 (5): 904–917. https://doi.org/10.1128/mcb.00951-12.CrossRefPubMedPubMedCentral

24.

Timper, K., J.L. Denson, S.M. Steculorum, C. Heilinger, L. Engstrom-Ruud, C.M. Wunderlich, S. Rose-John, F.T. Wunderlich, and J.C. Bruning. 2017. IL-6 Improves Energy and Glucose Homeostasis in Obesity via Enhanced Central IL-6 trans-Signaling. Cell Reports 19 (2): 267–280. https://doi.org/10.1016/j.celrep.2017.03.043.CrossRefPubMed

25.

Moreno-Indias, I., and F.J. Tinahones. 2015. Impaired adipose tissue expandability and lipogenic capacities as ones of the main causes of metabolic disorders. Journal Diabetes Research 2015: 970375. https://doi.org/10.1155/2015/970375.CrossRef

26.

Yang, Y., D. Ju, M. Zhang, and G. Yang. 2008. Interleukin-6 stimulates lipolysis in porcine adipocytes. Endocrine 33 (3): 261–269. https://doi.org/10.1007/s12020-008-9085-7.CrossRef

27.

Petersen, E.W., A.L. Carey, M. Sacchetti, G.R. Steinberg, S.L. Macaulay, M.A. Febbraio, and B.K. Pedersen. 2005. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. American Journal of Physiology. Endocrinology and Metabolism 288 (1): E155–E162. https://doi.org/10.1152/ajpendo.00257.2004.CrossRefPubMed

28.

Petruzzelli, M., M. Schweiger, R. Schreiber, R. Campos-Olivas, M. Tsoli, J. Allen, M. Swarbrick, S. Rose-John, M. Rincon, G. Robertson, R. Zechner, and E.F. Wagner. 2014. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metabolism 20 (3): 433–447. https://doi.org/10.1016/j.cmet.2014.06.011. CrossRefPubMed

29.

Morelli, M., M. Gaggini, G. Daniele, P. Marraccini, R. Sicari, and A. Gastaldelli. 2013. Ectopic fat: the true culprit linking obesity and cardiovascular disease? Thrombosis and Haemostasis 110 (4): 651–660. https://doi.org/10.1160/th13-04-0285.CrossRefPubMed

30.

Gaggini, M., C. Saponaro, and A. Gastaldelli. 2015. Not all fats are created equal: adipose vs. ectopic fat, implication in cardiometabolic diseases. Horm Mol Biol Clin Investig 22 (1): 7–18. https://doi.org/10.1515/hmbci-2015-0006.CrossRefPubMed

31.

Abdullahi, A., and M.G. Jeschke. 2016. White Adipose Tissue Browning: A Double-edged Sword. Trends in Endocrinology and Metabolism 27 (8): 542–552. https://doi.org/10.1016/j.tem.2016.06.006.CrossRefPubMed

32.

Wueest, S., F. Item, F.C. Lucchini, T.D. Challa, W. Muller, M. Bluher, and D. Konrad. 2016. Mesenteric Fat Lipolysis Mediates Obesity-Associated Hepatic Steatosis and Insulin Resistance. Diabetes 65 (1): 140–148. https://doi.org/10.2337/db15-0941. CrossRefPubMed

33.

Perry, R.J., J.G. Camporez, R. Kursawe, P.M. Titchenell, D. Zhang, C.J. Perry, M.J. Jurczak, et al. 2015. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 160 (4): 745–758. https://doi.org/10.1016/j.cell.2015.01.012. CrossRefPubMedPubMedCentral

34.

Wueest, S., C.I. Laesser, M. Boni-Schnetzler, F. Item, F.C. Lucchini, M. Borsigova, W. Muller, M.Y. Donath, and D. Konrad. 2018. IL-6-Type Cytokine Signaling in Adipocytes Induces Intestinal GLP-1 Secretion. Diabetes 67 (1): 36–45. https://doi.org/10.2337/db17-0637.CrossRefPubMed

35.

Wueest, S., and D. Konrad. 2018. The role of adipocyte-specific IL-6-type cytokine signaling in FFA and leptin release. Adipocyte 7 (3): 226–228. https://doi.org/10.1080/21623945.2018.1493901.CrossRefPubMedPubMedCentral

36.

Akiyama, Y., N. Kajimura, J. Matsuzaki, Y. Kikuchi, N. Imai, M. Tanigawa, and K. Yamaguchi. 1997. In vivo effect of recombinant human leukemia inhibitory factor in primates. Japanese Journal of Cancer Research 88 (6): 578–583.CrossRef

37.

Nicola, N.A., and J.J. Babon. 2015. Leukemia inhibitory factor (LIF). Cytokine & Growth Factor Reviews 26 (5): 533–544. https://doi.org/10.1016/j.cytogfr.2015.07.001.CrossRef

38.

Aubert, J., S. Dessolin, N. Belmonte, M. Li, F.R. McKenzie, L. Staccini, P. Villageois, B. Barhanin, A. Vernallis, A.G. Smith, G. Ailhaud, and C. Dani. 1999. Leukemia inhibitory factor and its receptor promote adipocyte differentiation via the mitogen-activated protein kinase cascade. The Journal of Biological Chemistry 274 (35): 24965–24972.CrossRef

39.

Gimble, J.M., F. Wanker, C.S. Wang, H. Bass, X. Wu, K. Kelly, G.D. Yancopoulos, and M.R. Hill. 1994. Regulation of bone marrow stromal cell differentiation by cytokines whose receptors share the gp130 protein. Journal of Cellular Biochemistry 54 (1): 122–133. https://doi.org/10.1002/jcb.240540113.CrossRefPubMed

40.

Hogan, J.C., and J.M. Stephens. 2005. Effects of leukemia inhibitory factor on 3T3-L1 adipocytes. The Journal of Endocrinology 185 (3): 485–496. https://doi.org/10.1677/joe.1.05980. CrossRef

41.

White, U.A., W.C. Stewart, R.L. Mynatt, and J.M. Stephens. 2008. Neuropoietin attenuates adipogenesis and induces insulin resistance in adipocytes. The Journal of Biological Chemistry 283 (33): 22505–22512. https://doi.org/10.1074/jbc.M710462200.CrossRefPubMedPubMedCentral

42.

Mori, M., K. Yamaguchi, and K. Abe. 1989. Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia. Biochemical and Biophysical Research Communications 160 (3): 1085–1092.CrossRef

43.

Metcalf, D., N.A. Nicola, and D.P. Gearing. 1990. Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood 76 (1): 50–56.CrossRef

44.

Marshall, M.K., W. Doerrler, K.R. Feingold, and C. Grunfeld. 1994. Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes. Endocrinology 135 (1): 141–147. https://doi.org/10.1210/endo.135.1.8013346.CrossRef

45.

Arora, G.K., A. Gupta, S. Narayanan, T. Guo, P. Iyengar, and R.E. Infante. 2018. Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin. JCI Insight 3 (14). https://doi.org/10.1172/jci.insight.121221.

46.

Beretta, E., H. Dhillon, P.S. Kalra, and S.P. Kalra. 2002. Central LIF gene therapy suppresses food intake, body weight, serum leptin and insulin for extended periods. Peptides 23 (5): 975–984.CrossRef

47.

Grossberg, A.J., J.M. Scarlett, X. Zhu, D.D. Bowe, A.K. Batra, T.P. Braun, and D.L. Marks. 2010. Arcuate nucleus proopiomelanocortin neurons mediate the acute anorectic actions of leukemia inhibitory factor via gp130. Endocrinology 151 (2): 606–616. https://doi.org/10.1210/en.2009-1135.CrossRefPubMed

48.

Lee, S., J. Lee, G.M. Kang, and M.S. Kim. 2018. Leptin directly regulate intrinsic neuronal excitability in hypothalamic POMC neurons but not in AgRP neurons in food restricted mice. Neuroscience Letters 681: 105–109. https://doi.org/10.1016/j.neulet.2018.05.041.CrossRefPubMed

49.

Miller, R.G., J.H. Petajan, W.W. Bryan, C. Armon, R.J. Barohn, J.C. Goodpasture, R.J. Hoagland, G.J. Parry, M.A. Ross, and S.C. Stromatt. 1996. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis rhCNTF ALS Study Group. Ann Neurol 39 (2): 256–260. https://doi.org/10.1002/ana.410390215.CrossRef

50.

A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. 1996. Neurology 46 (5): 1244–1249.CrossRef

51.

Bluher, S., S. Moschos, J. Bullen Jr., E. Kokkotou, E. Maratos-Flier, S.J. Wiegand, M.W. Sleeman, and C.S. Mantzoros. 2004. Ciliary neurotrophic factorAx15 alters energy homeostasis, decreases body weight, and improves metabolic control in diet-induced obese and UCP1-DTA mice. Diabetes 53 (11): 2787–2796.CrossRef

52.

Ott, V., M. Fasshauer, A. Dalski, H.H. Klein, and J. Klein. 2002. Direct effects of ciliary neurotrophic factor on brown adipocytes: evidence for a role in peripheral regulation of energy homeostasis. The Journal of Endocrinology 173 (2): R1–R8.CrossRef

53.

Liu, Q.S., M. Gao, S.Y. Zhu, S.J. Li, L. Zhang, Q.J. Wang, and G.H. Du. 2007. The novel mechanism of recombinant human ciliary neurotrophic factor on the anti-diabetes activity. Basic & Clinical Pharmacology & Toxicology 101 (2): 78–84. https://doi.org/10.1111/j.1742-7843.2007.00092.x.CrossRef

54.

Watt, M.J., A. Hevener, G.I. Lancaster, and M.A. Febbraio. 2006. Ciliary neurotrophic factor prevents acute lipid-induced insulin resistance by attenuating ceramide accumulation and phosphorylation of c-Jun N-terminal kinase in peripheral tissues. Endocrinology 147 (5): 2077–2085. https://doi.org/10.1210/en.2005-1074.CrossRefPubMed

55.

Watt, M.J., N. Dzamko, W.G. Thomas, S. Rose-John, M. Ernst, D. Carling, B.E. Kemp, M.A. Febbraio, and G.R. Steinberg. 2006. CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nature Medicine 12 (5): 541–548. https://doi.org/10.1038/nm1383.CrossRefPubMed

56.

Duff, E., C.L. Li, D.L. Hartzell, Y.H. Choi, M.A. Della-Fera, and C.A. Baile. 2004. Ciliary neurotrophic factor injected icv induces adipose tissue apoptosis in rats. Apoptosis 9 (5): 629–634. https://doi.org/10.1023/B:APPT.0000038042.31683.7b.CrossRef

57.

Kokoeva, M.V., H. Yin, and J.S. Flier. 2005. Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. Science 310 (5748): 679–683. https://doi.org/10.1126/science.1115360. CrossRefPubMed

58.

Jin, H., R. Yang, G.A. Keller, A. Ryan, A. Ko, D. Finkle, T.A. Swanson, W. Li, D. Pennica, W.I. Wood, and N.F. Paoni. 1996. In vivo effects of cardiotrophin-1. Cytokine 8 (12): 920–926. https://doi.org/10.1006/cyto.1996.0123. CrossRefPubMed

59.

Zvonic, S., J.C. Hogan, P. Arbour-Reily, R.L. Mynatt, and J.M. Stephens. 2004. Effects of cardiotrophin on adipocytes. The Journal of Biological Chemistry 279 (46): 47572–47579. https://doi.org/10.1074/jbc.M403998200.CrossRefPubMed

60.

Moreno-Aliaga, M.J., N. Perez-Echarri, B. Marcos-Gomez, E. Larequi, F.J. Gil-Bea, B. Viollet, I. Gimenez, J.A. Martinez, J. Prieto, and M. Bustos. 2011. Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metabolism 14 (2): 242–253. https://doi.org/10.1016/j.cmet.2011.05.013.CrossRefPubMed

61.

Lopez-Yoldi, M., M. Fernandez-Galilea, L.M. Laiglesia, E. Larequi, J. Prieto, J.A. Martinez, M. Bustos, and M.J. Moreno-Aliaga. 2014. Cardiotrophin-1 stimulates lipolysis through the regulation of main adipose tissue lipases. Journal of Lipid Research 55 (12): 2634–2643. https://doi.org/10.1194/jlr.M055335.CrossRefPubMedPubMedCentral

62.

Lopez-Yoldi, M., B. Marcos-Gomez, M.A. Romero-Lozano, N. Sainz, J. Prieto, J.A. Martinez, M. Bustos, and M.J. Moreno-Aliaga. 2017. Cardiotrophin-1 Regulates Adipokine Production in 3T3-L1 Adipocytes and Adipose Tissue From Obese Mice. Journal of Cellular Physiology 232 (9): 2469–2477. https://doi.org/10.1002/jcp.25590.CrossRefPubMed

63.

Zhu, S., F. Sun, W. Li, Y. Cao, C. Wang, Y. Wang, D. Liang, R. Zhang, S. Zhang, H. Wang, and F. Cao. 2011. Apelin stimulates glucose uptake through the PI3K/Akt pathway and improves insulin resistance in 3T3-L1 adipocytes. Molecular and Cellular Biochemistry 353 (1–2): 305–313. https://doi.org/10.1007/s11010-011-0799-0.CrossRefPubMed

64.

Vespasiani-Gentilucci, U., A. De Vincentis, J. Argemi, G. Galati, E. Anso, G. Patti, and A. Picardi. 2013. Cardiotrophin-1 is not associated with carotid or coronary disease and is inversely associated with obesity in patients undergoing coronary angiography. Archives of Medical Science 9 (4): 635–639. https://doi.org/10.5114/aoms.2013.37272.CrossRefPubMed

65.

Hung, H.C., F.H. Lu, H.Y. Ou, H.T. Wu, J.S. Wu, Y.C. Yang, and C.J. Chang. 2013. Increased cardiotrophin-1 in subjects with impaired glucose tolerance and newly diagnosed diabetes. International Journal of Cardiology 169 (3): e33–e34. https://doi.org/10.1016/j.ijcard.2013.08.112.CrossRefPubMed

66.

Hung, H.C., F.H. Lu, H.T. Wu, H.Y. Ou, Y.C. Yang, J.S. Wu, and C.J. Chang. 2015. Cardiotrophin-1 is inversely associated with obesity in non-diabetic individuals. Scientific Reports 5: 17438. https://doi.org/10.1038/srep17438.CrossRefPubMedPubMedCentral

67.

Natal, C., M.A. Fortuno, P. Restituto, A. Bazan, I. Colina, J. Diez, and N. Varo. 2008. Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. American Journal of Physiology. Endocrinology and Metabolism 294 (1): E52–E60. https://doi.org/10.1152/ajpendo.00506.2007.CrossRefPubMed

68.

Rendo-Urteaga, T., S. Garcia-Calzon, E. Martinez-Anso, M. Chueca, M. Oyarzabal, M.C. Azcona-Sanjulian, M. Bustos, M.J. Moreno-Aliaga, J.A. Martinez, and A. Marti. 2013. Decreased cardiotrophin-1 levels are associated with a lower risk of developing the metabolic syndrome in overweight/obese children after a weight loss program. Metabolism 62 (10): 1429–1436. https://doi.org/10.1016/j.metabol.2013.05.011.CrossRefPubMed

69.

Rose, T.M., and A.G. Bruce. 1991. Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6. Proceedings of the National Academy of Sciences of the United States of America 88 (19): 8641–8645.CrossRef

70.

Rose, T.M., M.J. Lagrou, I. Fransson, B. Werelius, O. Delattre, G. Thomas, P.J. de Jong, G.J. Todaro, and J.P. Dumanski. 1993. The genes for oncostatin M (OSM) and leukemia inhibitory factor (LIF) are tightly linked on human chromosome 22. Genomics 17 (1): 136–140. https://doi.org/10.1006/geno.1993.1294.CrossRefPubMed

71.

Tanaka, M., T. Hara, N.G. Copeland, D.J. Gilbert, N.A. Jenkins, and A. Miyajima. 1999. Reconstitution of the functional mouse oncostatin M (OSM) receptor: molecular cloning of the mouse OSM receptor beta subunit. Blood 93 (3): 804–815.CrossRef

72.

Sanchez-Infantes, D., U.A. White, C.M. Elks, R.F. Morrison, J.M. Gimble, R.V. Considine, A.W. Ferrante, E. Ravussin, and J.M. Stephens. 2014. Oncostatin m is produced in adipose tissue and is regulated in conditions of obesity and type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 99 (2): E217–E225. https://doi.org/10.1210/jc.2013-3555.CrossRefPubMed

73.

Komori, T., M. Tanaka, E. Senba, A. Miyajima, and Y. Morikawa. 2013. Lack of oncostatin M receptor beta leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype. The Journal of Biological Chemistry 288 (30): 21861–21875. https://doi.org/10.1074/jbc.M113.461905.CrossRefPubMedPubMedCentral

74.

Komori, T., M. Tanaka, E. Senba, A. Miyajima, and Y. Morikawa. 2014. Deficiency of oncostatin M receptor beta (OSMRbeta) exacerbates high-fat diet-induced obesity and related metabolic disorders in mice. The Journal of Biological Chemistry 289 (20): 13821–13837. https://doi.org/10.1074/jbc.M113.542399.CrossRefPubMedPubMedCentral

75.

Komori, T., M. Tanaka, H. Furuta, T. Akamizu, A. Miyajima, and Y. Morikawa. 2015. Oncostatin M is a potential agent for the treatment of obesity and related metabolic disorders: a study in mice. Diabetologia 58 (8): 1868–1876. https://doi.org/10.1007/s00125-015-3613-9.CrossRefPubMed

76.

Hattori, K., T. Sumi, T. Yasui, M. Morimura, H. Nobeyama, E. Okamoto, M. Noriyuki, K. Honda, H. Kiyama, and O. Ishiko. 2004. VEGF mRNA in adipocytes increase with rebound weight-gain after diet-restriction. International Journal of Molecular Medicine 13 (3): 395–399.PubMed

77.

Rega, G., C. Kaun, S. Demyanets, S. Pfaffenberger, K. Rychli, P.J. Hohensinner, S.P. Kastl, W.S. Speidl, T.W. Weiss, J.M. Breuss, A. Furnkranz, P. Uhrin, J. Zaujec, V. Zilberfarb, M. Frey, R. Roehle, G. Maurer, K. Huber, and J. Wojta. 2007. Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin m in human adipose tissue in vitro and in murine adipose tissue in vivo. Arteriosclerosis, Thrombosis, and Vascular Biology 27 (7): 1587–1595. https://doi.org/10.1161/atvbaha.107.143081.CrossRef

78.

Miyaoka, Y., M. Tanaka, T. Naiki, and A. Miyajima. 2006. Oncostatin M inhibits adipogenesis through the RAS/ERK and STAT5 signaling pathways. The Journal of Biological Chemistry 281 (49): 37913–37920. https://doi.org/10.1074/jbc.M606089200.CrossRef

79.

Heinrich, P.C., I. Behrmann, S. Haan, H.M. Hermanns, G. Muller-Newen, and F. Schaper. 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. The Biochemical Journal 374 (Pt 1): 1–20. https://doi.org/10.1042/bj20030407.CrossRefPubMedPubMedCentral

Title: Review: the Roles and Mechanisms of Glycoprotein 130 Cytokines in the Regulation of Adipocyte Biological Function
Authors: Dufang Ma
Yong Wang
Guofeng Zhou
Yongcheng Wang
Xiao Li
Publication date: 01-06-2019
Publisher: Springer US
Keywords: Obesity
Obesity
Insulins
Lipolysis
Lipolysis
Cytokines
Insulins
Leukemia
Published in: Inflammation / Issue 3/2019
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-019-00959-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Attenuation of Sepsis-Induced Cardiomyopathy by Regulation of MicroRNA-23b Is Mediated Through Targeting of MyD88-Mediated NF-κB Activation

Chinese Birch Pollen Allergy and Immunotherapy in Mice

Intrauterine Inflammation Damages Placental Angiogenesis via Wnt5a-Flt1 Activation

Neutrophil Cytosolic Factor 1 Contributes to the Development of Sepsis

Correction to: The Influence of a Xanthine-Catechin Chemical Matrix on in vitro Macrophage-Activation Triggered by Antipsychotic Ziprasidone

Aging and Hyperglycemia Intensify Dyslipidemia-Induced Oxidative Stress and Inflammation in Rats: Assessment of Restorative Potentials of ALA and EPA + DHA

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage